NEW YORK and ROME, Ga., Aug. 5, 2025 /PRNewswire/ -- The VERTEX Companies, LLC ("VERTEX"), a global professional services firm delivering expert, forensic, construction project advisory, and ...

KING OF PRUSSIA, June 10, 2025 (GLOBE NEWSWIRE) -- Vertex Inc. (NASDAQ:VERX) (“Vertex” or the “Company”), a leading global provider of indirect tax solutions, today announced it has been selected to ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the initiation of a global pivotal Phase 3 development program for fixed-dose combinations of ...

KING OF PRUSSIA, June 10, 2025 (GLOBE NEWSWIRE) -- Vertex Inc. (VERX) (NASDAQ:VERX) (“Vertex” or the “Company”), a leading global provider of indirect tax solutions, today announced it has been ...

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today a new $750,000 program to support the work of young faculty who are newly establishing independent research ...

KING OF PRUSSIA, Pa., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ:VERX) (“Vertex” or the “Company”), a leading provider of tax technology and services, announced that it is extending its ...

Jupiter Endovascular, Inc. announced it has closed a Series B financing round that surpassed its $40 million target. Accordin ...

- VX-264 Phase 1/2 enrollment and dosing complete in Parts A and B: VX-264 was generally safe and well tolerated; efficacy data are not supportive of further clinical advancement - - Zimislecel ...